BMRA vs NPCE โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
NPCE Captures Institutional Edge (3โ1 Pillars ยท 7โ3 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Neuropace, Inc. Common Stock (NPCE) driven by superior Valuation, Growth & Margin, Momentum & Technical while BMRA counters with relative strength in Options & Structure. Fundamentally, BMRA trades at N/M Forward P/E with -125.2% operating margin (-8.3% YoY revenue) versus NPCE at 138.9x Forward P/E and -11.3% operating margin (-15.5% YoY). In options structure, BMRA sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against NPCE sits in BREAKDOWN (45th %ile IV; Dealer Gamma Walls on Pro).
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | BMRA Revenue | NPCE Revenue | BMRA Op. Margin | NPCE Op. Margin | Margin Edge |
|---|---|---|---|---|---|
| FY2019 | $10M | N/A | -46.4% | N/A | BMRA |
| FY2020 | $10M | $40M | -41.0% | -31.7% | NPCE |
| FY2021 | $10M | $50M | -104.2% | -52.5% | NPCE |
| FY2022 | $20M | $50M | -24.0% | -89.6% | BMRA |
| FY2023 | $10M | $70M | -135.3% | -41.5% | NPCE |
| FY2024 | $10M | $80M | -117.6% | -27.1% | NPCE |
| FY2025 | $10M | $100M | -96.7% | -16.3% | NPCE |
| FY2026 | $0M | N/A | -119.5% | N/A | BMRA |
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | BMRA | NPCE | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $6.0M | $412.6M | Larger Scale | NPCE |
| Trailing P/E Ratio Valuation | N/M | 138.9x | Lower Multiple | NPCE |
| Forward P/E Ratio Valuation | N/M | 138.9x | Lower Multiple | NPCE |
| Revenue Growth (YoY) Growth | -8.3% | -15.5% | Higher Growth | BMRA |
| Operating Margin (TTM) Profitability | -125.2% | -11.3% | Higher Margin | NPCE |
| Net Profit Margin Profitability | -115.5% | -18.4% | Higher Margin | NPCE |
| Return on Equity (ROE) Capital Efficiency | -113.8% | -106.5% | Higher ROE | NPCE |
| 52-Week Range Position Momentum | 5% ($1โ$3) | 16% ($5โ$20) | Stronger Trend | NPCE |
| Beta / 30D Volatility Risk Regime | 0.67ฮฒ ยท 62% Vol | 1.35ฮฒ ยท 138% Vol | Lower Realized Risk | BMRA |
| Unified Institutional Score Composite Signal | 44.5 / 100 (HOLD) | 41.0 / 100 (SELL) | Higher Composite | BMRA |